Skip to content
Home/Companies/Biotech/Centogene

Centogene

Biotech·Germany·Exited 2019·Held 2yr
Entry
2017
Hold
2yr
Exit
2019

Who owns Centogene?

Centogene was owned by DPE Deutsche Private Equity through DPE Fund III (2017 vintage) from 2017 to 2019, exited via IPO.

Hand-verified · updated 2026-07-03

DPE Deutsche Private Equity
Investor
DPE Deutsche Private Equity
DPE Fund III · 2017 · Buyout

Key facts

HQGermany
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2019

More from DPE Fund III

Other portfolio companies in the same fund.

Ortheum
Ortheum
Active
HealthcareGermany· 2022
BplusL
BplusL
Active
Business ServicesGermany· 2020
Mehler Vario System
Active
Aerospace & DefenceGermany· 2020
Mehler Vario Systems
Mehler Vario Systems
Active
Aerospace & DefenceGermany· 2020
VTU Group
Exited 2023
Business ServicesAustria· 2020
to
BE-terna
Exited 2022
IT ServicesAustria· 2019
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Centogene

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Centogene?

6 strategic and 114financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Centogene.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue